𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Oral administration of the methanol extraction residue of BCG (MER/BCG): A phase I study in non-oat cell lung cancer patients

✍ Scribed by A.H. Bartal; D. Mordohovich; C. Lichtig; T. Mekori; E. Robinson

Publisher
Elsevier Science
Year
1983
Tongue
English
Weight
458 KB
Volume
5
Category
Article
ISSN
0192-0561

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination chemotherapy with and withou
Combination chemotherapy with and without the methanol-extracted residue of bacillus calmette-guerin (MER) in extensive non-small-cell lung cancer: A prospective randomized study for the piedmont oncology association
✍ Frederick Richards II; Virginia Howard; Anita Shore; Hyman B. Muss; Douglas R. W 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 498 KB 👁 2 views

One-hundred-three patients with extensive non-small-cell lung cancer were entered into a prospective, randomized trial to determine the value of MER as an adjuvant to chemotherapy. Patients were stratified according to histology and performance status. All patients received CCNU, methotrexate, and A

A Phase I–II study of sequential adminis
A Phase I–II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma
✍ Tony S. K. Mok; Herman Wong; Benny Zee; Kwok Hung Yu; Thomas W. T. Leung; Tak Wa 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 1 views

## Abstract ## BACKGROUND Topotecan (9‐dimethylaminomethyl‐10‐hydroxycampthothecin) is a new topoisomerase I inhibitor with promising efficacy in the treatment of patients with small cell lung carcinoma (SCLC). Combination with a topoisomerase II inhibitor may potentate the therapeutic effect of t